AAAAAA

   
Results: 1-8 |
Results: 8
CELLULAR KINETICS OF INDUCTION BY OLTIPRAZ AND ITS KETO DERIVATIVE OFDETOXICATION ENZYMES IN HUMAN COLON ADENOCARCINOMA CELLS
Authors: ODWYER PJ CLAYTON M HALBHERR T MYERS CB YAO KS
Citation: Pj. Odwyer et al., CELLULAR KINETICS OF INDUCTION BY OLTIPRAZ AND ITS KETO DERIVATIVE OFDETOXICATION ENZYMES IN HUMAN COLON ADENOCARCINOMA CELLS, Clinical cancer research, 3(5), 1997, pp. 783-791
PHASE-II TRIAL OF DEXAMETHASONE (DEX) AND 13-CIS-RETINOIC ACID (CRA) AS FIRST-LINE TREATMENT FOR MULTIPLE-MYELOMA
Authors: SCHILDER RJ MILLENSON MM ENTMACHER M ROGATKO A YESLOW G HALBHERR T PADAVICSHALLER K YOUNG RC SMITH MR
Citation: Rj. Schilder et al., PHASE-II TRIAL OF DEXAMETHASONE (DEX) AND 13-CIS-RETINOIC ACID (CRA) AS FIRST-LINE TREATMENT FOR MULTIPLE-MYELOMA, Blood, 90(10), 1997, pp. 4141-4141
PHASE-II TRIAL OF FLUDARABINE ALTERNATING WITH INTERFERON (IFN)ALPHA-2B IN LOW-GRADE NON-HODGKINS-LYMPHOMA (NHL)
Authors: SMITH MR BOYD RL MINNITTI C CLYDE J HOESSLY MC CORNFELD M YESLOW G HALBHERR T ROGATKO A SCHILDER RJ YOUNG RC MILLENSON MM
Citation: Mr. Smith et al., PHASE-II TRIAL OF FLUDARABINE ALTERNATING WITH INTERFERON (IFN)ALPHA-2B IN LOW-GRADE NON-HODGKINS-LYMPHOMA (NHL), Blood, 90(10), 1997, pp. 861-861
PHASE-II TRIAL OF PEND CHEMOTHERAPY IN RELAPSED OR REFRACTORY HODGKINS-DISEASE
Authors: SMITH MR VARTERASIAN M KARANES C PEMBERTON P YESLOW G HALBHERR T SCHILDER RJ MILLENSON MM ALKATIB AM
Citation: Mr. Smith et al., PHASE-II TRIAL OF PEND CHEMOTHERAPY IN RELAPSED OR REFRACTORY HODGKINS-DISEASE, Blood, 90(10), 1997, pp. 1519-1519
PHASE-I TRIAL OF BUTHIONINE SULFOXIMINE IN COMBINATION WITH MELPHALANIN PATIENTS WITH CANCER
Authors: ODWYER PJ HAMILTON TC LACRETA FP GALLO JM KILPATRICK D HALBHERR T BRENNAN J BOOKMAN MA HOFFMAN J YOUNG RC COMIS RL OZOLS RF
Citation: Pj. Odwyer et al., PHASE-I TRIAL OF BUTHIONINE SULFOXIMINE IN COMBINATION WITH MELPHALANIN PATIENTS WITH CANCER, Journal of clinical oncology, 14(1), 1996, pp. 249-256
COMBINED-MODALITY TREATMENT OF PATIENTS WITH EARLY CLINICALLY STAGED HODGKINS-DISEASE
Authors: SCHILDER RJ MILLENSON MM COIA LR ALSALEEM T KESSLER HB YESLOW G HALBHERR T YOUNG RC SMITH MR
Citation: Rj. Schilder et al., COMBINED-MODALITY TREATMENT OF PATIENTS WITH EARLY CLINICALLY STAGED HODGKINS-DISEASE, Blood, 88(10), 1996, pp. 354-354
TIME-DEPENDENT PHARMACODYNAMIC MODELS IN CANCER-CHEMOTHERAPY - POPULATION PHARMACODYNAMIC MODEL FOR GLUTATHIONE DEPLETION FOLLOWING MODULATION BY BUTHIONINE SULFOXIMINE (BSO) IN A PHASE-I TRIAL OF MELPHALAN AND BSO
Authors: GALLO JM BRENNAN J HAMILTON TC HALBHERR T LAUB PB OZOLS RF ODWYER PJ
Citation: Jm. Gallo et al., TIME-DEPENDENT PHARMACODYNAMIC MODELS IN CANCER-CHEMOTHERAPY - POPULATION PHARMACODYNAMIC MODEL FOR GLUTATHIONE DEPLETION FOLLOWING MODULATION BY BUTHIONINE SULFOXIMINE (BSO) IN A PHASE-I TRIAL OF MELPHALAN AND BSO, Cancer research, 55(20), 1995, pp. 4507-4511
CLINICAL, PHARMACOKINETIC AND BIOLOGICAL STUDIES OF TOPOTECAN
Authors: ODWYER PJ LACRETA FP HAAS NB HALBHERR T FRUCHT H GOOSENBERG E YAO KS
Citation: Pj. Odwyer et al., CLINICAL, PHARMACOKINETIC AND BIOLOGICAL STUDIES OF TOPOTECAN, Cancer chemotherapy and pharmacology, 34, 1994, pp. 190000046-190000052
Risultati: 1-8 |